3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Gastrointestinal
2
Dermatologic
2
Breast
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Conditions
Melanoma
4
Carcinoma, Renal Cell
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Merkel Cell
1
Interventions
pembrolizumab
30
Nivolumab
15
Paclitaxel
13
Cyclophosphamide
12
Carboplatin
12
sacituzumab govitecan
8
Cisplatin
8
Capecitabine
7
130-nm albumin-bound paclitaxel
7
Gemcitabine
6
fludarabine
5
durvalumab
5
avelumab
5
atezolizumab
5
Magnetic Resonance Spectroscopy
5
Ipilimumab
5
Biopsy
5
camrelizumab
4
Specimen Handling
4
Interleukin-2
4
Injections
4
Immune Checkpoint Inhibitors
4
Docetaxel
4
toripalimab
3
talazoparib
3
Leucovorin
3
Everolimus
3
Clinical Trials, Phase II as Topic
3
Bevacizumab
3
yeast-CEA vaccine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Triple Negative Breast Neoplasms
×
bempegaldesleukin
×
Clear all
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts
NCT03435640
2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2
Terminated
64 enrolled
22 charts